Skip to main content
Fig. 2 | Trials

Fig. 2

From: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial

Fig. 2

Schedule of screening, enrolment, interventions, and assessments. *Assessments listed are limited to the study-specific assessments. In addition to these, several assessments are performed on all study participants as per standard of care procedures. W, week; M, month; MGIT, Mycobacteria Growth Incubator Tube. ** Individualization of treatment occurs when drug susceptibility test results become available (whole genome sequencing for the experimental arm; line probe assays and phenotypic drug susceptibility test for standard of care arm). This is expected to occur a median of 5 to 6 weeks after the start of treatment. ***Closeout is performed at month 6 for patients who receive a 6-month treatment regimen

Back to article page

Trials

ISSN: 1745-6215